Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPA‐REG OUTCOME</scp> trial
Christoph Wanner(University of Würzburg), Jyothis T. George(Boehringer Ingelheim (China)), Audrey Koitka‐Weber(Boehringer Ingelheim (Germany)), Maximilian von Eynatten(Nestlé (Switzerland)), Silvio E. Inzucchi(Yale University), Sibylle J. Hauske(Heidelberg University), Bernard Zinman(Mount Sinai Hospital), Michaela Mattheus(Boehringer Ingelheim (Germany))
Cited by 36
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
|Diabetes Care|2012|3.2k